盐酸倍他司汀联合吡拉西坦治疗缺血性眩晕症患者的临床研究  

Clinical trial of betahistine hydrochloride combined with piracetam in the patients with ischemic vertigo

作　　者：谢志彬[1] 吴行才 周建军[2] 官测林 XIE Zhi-bin;WU Hang-cai;ZHOU Jian-jun;GUAN Ce-lin(Rehabilitation Department,Longyan First Hospital,Longyan 364000,Fujian Province,China;Neurosurgery Department,Longyan First Hospital,Longyan 364000,Fujian Province,China)

机构地区：[1]福建省龙岩市第一医院康复科,福建龙岩364000 [2]福建省龙岩市第一医院神经外科,福建龙岩364000

出　　处：《中国临床药理学杂志》2023年第22期3218-3222,共5页The Chinese Journal of Clinical Pharmacology

摘　　要：目的观察盐酸倍他司汀联合吡拉西坦治疗缺血性眩晕症患者的临床疗效及安全性。方法将缺血性眩晕症患者分为对照组和试验组。对照组给予盐酸倍他司汀注射液10~30 mg治疗,qd;试验组在对照组基础上加20%吡拉西坦氯化钠注射液静脉滴注治疗,qd,2组患者均持续治疗2周。比较2组患者的临床疗效,治疗前后2组患者椎动脉(VA)、基底动脉和大脑后动脉平均血流速度(Vm)、血清一氧化氮(NO)、内皮素^(-1)(ET^(-1))、血清维生素D结合蛋白(DBP)、同型半胱氨酸(Hcy)及血液流变学指标,用汉化眩晕障碍量表(DHI)、Berg平衡量表(BBS)评估患者病情程度。比较2组患者药物不良反应及治疗后6个月复发率。结果治疗后,试验组和对照组的总有效率分别为91.84%和75.61%,差异有统计学意义(P<0.05)。治疗后,试验组和对照组的椎动脉Vm分别为(26.33±2.74)和(24.05±2.52)cm·s^(-1),基底动脉Vm分别为(39.02±4.01)和(35.11±3.67)cm·s^(-1),大脑后动脉Vm分别为(46.02±4.75)和(40.22±4.38)cm·s^(-1),NO分别为(105.64±11.27)和(92.26±9.37)pg·mL^(-1),ET^(-1)分别为(93.02±9.05)和(110.44±11.61)ng·L^(-1),DBP分别为(894.34±90.67)和(621.37±63.55)μg·mL^(-1),Hcy分别为(6.87±0.95)和(9.04±1.02)μmol·L^(-1),全血高切黏度分别为(4.87±0.49)和(5.97±0.60)mPa·s^(-1),全血低切黏度分别为(6.87±1.02)和(9.22±1.13)mPa·s^(-1),血浆黏度分别为(1.63±0.20)和(1.91±0.20)mPa·s^(-1),红细胞聚集指数分别为2.97±0.31和3.87±0.40,DHI评分分别为(20.94±2.23)和(30.27±2.61)分,BBS评分分别为(43.24±5.09)和(40.34±4.03)分。试验组上述指标与对照组比较,差异均有统计学意义(均P<0.05)。试验组、对照组治疗后药物不良反应总发生率分别为20.00%和33.33%,治疗后6个月复发率分别为2.22%和11.11%,差异均无统计学意义(均P>0.05)。结论盐酸倍他司汀联合吡拉西坦治疗缺血性眩晕症患者疗效较单一用药的临床更佳,改善患者脑�Objective To observe the clinical effect and safety of betahistine hydrochloride combined with piracetam in the treatment of ischemic vertigo.Methods Patients with ischemic vertigo were divided into control group and treatment group.The control group was treated with betahistine hydrochloride injection 10~30 mg,qd;patients in the treatment group were intravenous drip administered with 20%piracetam sodium chloride injection on the basis of the control group,qd,and both groups were treated for 2 weeks.The efficacy of the two groups was compared.The mean blood flow velocity(Vm)of vertebral artery(VA),basilar artery and posterior cerebral artery,serum nitric oxide(NO),endothelin-1(ET-1),serum vitamin D binding protein(DBP),homocysteine(Hcy)and hemorheological indexes were compared between the two groups before and after treatment.The severity of the patients was evaluated by Chinese vertigo disorder scale(DHI)and Berg balance scale(BBS).The adverse drug reactions and recurrence rate at 6 months after treatment were compared between the two groups.Results After treatment,the total effective rates of the treatment group and the control group were91.84%and 75.61%,respectively,and the difference was statistically significant(P<0.05).After treatment,the vertebral artery Vm of treatment group and control group were(26.33±2.74)and(24.05±2.52)cm·s^(-1),and the basilar artery Vm were(39.02±4.01)and(35.11±3.67)cm·s^(-1),respectively.Posterior cerebral artery Vm were(46.02±4.75)and(40.22±4.38)cm·s^(-1),and NO were(105.64±11.27)and(92.26±9.37)pg·mL^(-1),respectively.ET-1 were(93.02±9.05)and(110.44±11.61)ng·L^(-1);DBP were(894.34±90.67)and(621.37±63.55)μg·mL^(-1),respectively.Hcy were(6.87±0.95)and(9.04±1.02)μmol·L^(-1);whole blood high tangential viscosity were(4.87±0.49)and(5.97±0.60)mP a·s^(-1);whole blood low tangential viscosity were(6.87±1.02)and(9.22±1.13)mP a·s^(-1),respectively.Plasma viscosity were(1.63±0.20)and(1.91±0.20)mP a·s^(-1);erythrocyte aggregation index were 2.97±0.31 and 3.87�

关 键 词：倍他司汀 吡拉西坦 缺血性眩晕症 脑血流 血管内皮功能 维生素D结合蛋白 同型半胱氨酸 

分 类 号：R97[医药卫生—药品]